We perform state-of-the-art pre-clinical and clinical research studies in respiratory infections and airway diseases, to help translate new drugs into the clinic for treatment of respiratory viral infections and acute attacks of asthma and chronic obstructive pulmonary disease (COPD).
Traditionally, new medical entities (NMEs) entering early clinical development for asthma and COPD exacerbations require large scale, multi-centre multi-national field studies, which require hundreds/thousands of patients and take years to complete, with a vast accompanying cost to the pharmaceutical industry.
Here at Virtus Respiratory Research, we provide a new solution to this problem through human virus challenge studies, that will provide you the client, with early proof of concept and proof of mechanism rapidly, and at a fraction of the cost. Our vision is therefore to create a new way of testing NMEs in respiratory early clinical development, making clinical testing more efficient, and aiding go/no go decision making.
Virtus combines world class expertise in respiratory medicine with the professional service and management expected in the commercial sector; hence our unique tag line “an academic brain with a CRO’s body”.
Dr James Bolaji, Virtus Scientist
We partner with a range of clients from large pharmaceutical companies to biotechs to assist them in the development of new medicines for respiratory diseases.